The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies

被引：0

作者：

Giantzi, Virginia ^{[1
]}

Karapanayiotides, Theodoros ^{[1
]}

Lagoudaki, Roza ^{[1
,2
]}

Poulatsidou, Kyriaki-Nefeli ^{[1
,2
]}

Lourbopoulos, Athanasios ^{[1
,2
]}

Daniilidis, Michail ^{[1
,2
]}

Taskos, Nikolaos ^{[1
]}

Milonas, Loannis ^{[1
]}

Grigoriadis, Nikolaos ^{[1
,2
]}

机构：

[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol 2, GR-54006 Thessaloniki, Greece

[2] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Lab Expt Neurol & Neuroimmunol, GR-54006 Thessaloniki, Greece

来源：

EUROPEAN NEUROLOGY | 2016年 / 75卷 / 1-2期

关键词：

Neutralizing antibodies; Binding antibodies; Anti-interferon-beta antibodies; Multiple sclerosis; NEUTRALIZING ANTIBODIES; IFN-BETA; DIAGNOSTIC-CRITERIA; BINDING-ANTIBODIES; MS; CORTICOSTEROIDS; IFN-BETA-1B; THERAPY; TRIAL;

D O I：

10.1159/000444319

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background/Aims: We assessed the, hitherto unknown, impact of intravenous methylprednisolone (ivMP) pulses during relapses of multiple sclerosis (MS) on the kinetics of anti-interferon-beta neutralizing antibodies (Nabs) and binding antibodies (Babs). Methods: Babs (ELISA) and Nabs (antiviral cytopathic effect assay) titers were evaluated before, immediately after and at 1 month following ivMP in 60 MS patients. Results: ivMP reduces Nabs and Babs titers for at least 1 month. Baseline titers determine Nabs and Babs seronegativity at the end of ivMP. Clinical response to ivMP tends to be better in Nabs(+) patients. Conclusion: Sampling for Nabs/Babs should be avoided during or shortly after ivMP to avoid transient positive or negative results that may obscure the decision to switch treatment. (C) 2016 S. Karger AG, Basel

引用

页码：82 / 88

页数：7

共 50 条

[31] Neutralizing antibodies (NABS) and interferon beta-1B therapy of multiple sclerosis [J].

Horowski, R ;

Stürzebecker, CS ;

Kapp, JF .

FUNCTIONAL NEUROLOGY, 2001, 16 (02) :117-128

[32] Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report [J].

Marta, Monica ;

Baker, David ;

Creeke, Paul ;

Pryce, Gareth ;

Gnanapavan, Sharmilee ;

Giovannoni, Gavin .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56

[33] Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results [J].

Link, Jenny ;

Ramanujam, Ryan ;

Auer, Michael ;

Ryner, Malin ;

Hassler, Signe ;

Bachelet, Delphine ;

Mbogning, Cyprien ;

Warnke, Clemens ;

Buck, Dorothea ;

Jensen, Poul Erik Hyldgaard ;

Sievers, Claudia ;

Ingenhoven, Kathleen ;

Fissolo, Nicolas ;

Lindberg, Raija ;

Grummel, Verena ;

Donnellan, Naoimh ;

Comabella, Manuel ;

Montalban, Xavier ;

Kieseier, Bernd ;

Sorensen, Per Soelberg ;

Hartung, Hans-Peter ;

Derfuss, Tobias ;

Lawton, Andy ;

Sikkema, Dan ;

Pallardy, Marc ;

Hemmer, Bernhard ;

Deisenhammer, Florian ;

Broet, Philippe ;

Donnes, Pierre ;

Davidson, Julie ;

Fogdell-Hahn, Anna .

PLOS ONE, 2017, 12 (02)

[34] Formation of neutralizing antibodies during therapy of multiple sclerosis with interferon beta-1b. Practical procedure when treatment failure is suspected [J].

Walther, EU ;

Dang, T ;

Hartung, HP ;

Hohlfeld, R .

NERVENARZT, 1997, 68 (12) :935-939

[35] Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis [J].

Govindappa, Karthik ;

Sathish, Jean ;

Park, Kevin ;

Kirkham, Jamie ;

Pirmohamed, Munir .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (11) :1287-1298

[36] Should neutralizing antibodies be monitored during interferon-β treatment for multiple sclerosis? [J].

Oger, J ;

Gibbs, E .

NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (02) :76-77

[37] The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis [J].

Villani, Veronica ;

Prosperini, Luca ;

De Giglio, Laura ;

Pozzilli, Carlo ;

Salvetti, Marco ;

Sette, Giuliano .

HEADACHE, 2012, 52 (07) :1130-1135

[38] Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients [J].

Jensen, P. E. H. ;

Sellebjerg, F. ;

Sondergaard, H. B. ;

Sorensen, P. S. .

EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (10) :1311-1317

[39] The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study [J].

Paolicelli, D. ;

D'Onghia, M. ;

Pellegrini, F. ;

Direnzo, V. ;

Iaffaldano, P. ;

Lavolpe, V. ;

Trojano, M. .

JOURNAL OF NEUROLOGY, 2013, 260 (06) :1562-1568

[40] Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial [J].

Goodin, Douglas S. ;

Hartung, Hans-Peter ;

O'Connor, Paul ;

Filippi, Massimo ;

Arnason, Barry ;

Comi, Giancarlo ;

Cook, Stuart ;

Jeffery, Douglas ;

Kappos, Ludwig ;

Bogumil, Timon ;

Knappertz, Volker ;

Sandbrink, Rupert ;

Beckmann, Karola ;

White, Rick ;

Petkau, John ;

Pohl, Christoph .

MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (02) :181-195

← 1 2 3 4 5 →